Expert Discusses Potential Expansions to the Treatment Landscape in RCC

Treatment of renal cell carcinoma (RCC) is awaiting the potential integration of combinations of immuno-oncology agents like nivolumab (Opdivo) and ipilimumab (Yervoy), or combinations of targeted therapies with checkpoint inhibitors into the treatment paradigm. In an interview with Targeted Oncology, Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Read full article (External website)

1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply